Particle Therapy 2017

Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer. Speirs C, Bradley J, et al . J Thorac Oncol. 2017 Feb;12(2):293-301 RTPG 0617: 416 patients with Clinical Data, 322 patients analyzed for toxicity and dosimetry data. Multivariate analysis on 251 patient . Factors independently associated with worse Overall Survival: ● Increasing heart V50 (volume receiving ≥50 Gy), ● Heart volume, ● Lung V5 (lung structure [excluding the target volume]) receiving > 5 Gy), ● bilateral mediastinal lymph node involvement, ● lack of concurrent chemotherapy Heart V50 < 25% versus > 25% ● 1-year OS rates 70.2% versus 46.8% ● 2-year OS rates 45.9% versus 26.7% (p < 0.0001). Median heart V50 was significantly higher (20.8% versus 13.9%, p < 0.0001) for patients with any cardiac toxicity CONCLUSIONS: Heart dose is associated with OS and cardiac toxicity for patients with LA NSCLC treated with chemoradiotherapy.

‹#›